Japan's Teijin Pharma To Launch Gout Drug Uloric in Europe
Tokyo-based Teijin Pharma plans to launch gout drug Uloric (febuxostat) in European markets this fall after a March launch in the U.S. through licensee Takeda Pharmaceutical North America. The company also plans a NDA submission in Japan aiming for a 2011 domestic market launch. Billed as the first novel treatment for hyperuricemia in patients with gout in more than 40 years, the drug is expected to grow to achieve ¥100 billion in annual sales. (Click here for more - Japanese language
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights